NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

Published:2022-11 Issue:11 Volume:20 Page:1204-1214
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

von Mehren Margaret¹,Kane John M.²,Riedel Richard F.³,Sicklick Jason K.⁴,Pollack Seth M.⁵,Agulnik Mark⁶,Bui Marilyn M.⁷,Carr-Ascher Janai⁸,Choy Edwin⁹,Connelly Mary¹⁰,Dry Sarah¹¹,Ganjoo Kristen N.¹²,Gonzalez Ricardo J.⁷,Holder Ashley¹³,Homsi Jade¹⁴,Keedy Vicki¹⁵,Kelly Ciara M.¹⁶,Kim Edward¹⁷,Liebner David¹⁰,McCarter Martin¹⁸,McGarry Sean V.¹⁹,Mesko Nathan W.²⁰,Meyer Christian²¹,Pappo Alberto S.²²,Parkes Amanda M.²³,Petersen Ivy A.²⁴,Poppe Matthew²⁵,Schuetze Scott²⁶,Shabason Jacob²⁷,Spraker Matthew B.²⁸,Zimel Melissa²⁹,Bergman Mary Anne³⁰,Sundar Hema³⁰,Hang Lisa E.³⁰

Affiliation:

1. 1Fox Chase Cancer Center;

2. 2Roswell Park Comprehensive Cancer Center;

3. 3Duke Cancer Institute;

4. 4UC San Diego Moores Cancer Center;

5. 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

6. 6City of Hope National Medical Center;

7. 7Moffitt Cancer Center;

8. 8UC Davis Comprehensive Cancer Center;

9. 9Massachusetts General Hospital Cancer Center;

10. 10The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

11. 11UCLA Jonsson Comprehensive Cancer Center;

12. 12Stanford Cancer Institute;

13. 13O’Neal Comprehensive Cancer Center at UAB;

14. 14UT Southwestern Simmons Comprehensive Cancer Center;

15. 15Vanderbilt-Ingram Cancer Center;

16. 16Memorial Sloan Kettering Cancer Center;

17. 17Fred Hutchinson Cancer Center;

18. 18University of Colorado Cancer Center;

19. 19Fred & Pamela Buffett Cancer Center;

20. 20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

21. 21The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

22. 22St. Jude Children’s Research Hospital/University of Tennessee Health Science Center;

23. 23University of Wisconsin Carbone Cancer Center;

24. 24Mayo Clinic Cancer Center;

25. 25Huntsman Cancer Institute at the University of Utah;

26. 26University of Michigan Rogel Cancer Center;

27. 27Abramson Cancer Center at the University of Pennsylvania;

28. 28Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

29. 29UCSF Helen Diller Family Comprehensive Cancer Center; and

30. 30National Comprehensive Cancer Network.

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/11/article-p1204.xml

Reference146 articles.

1. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib;Cauchi;Cancer Chemother Pharmacol,2012

2. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998

3. Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and Notch pathway mutations;Burgoyne;JCO Precis Oncol,2017

4. Clinical management of gastrointestinal stromal tumors: before and after STI-571;Dematteo;Hum Pathol,2002

5. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial;Heinrich;Lancet Oncol,2020

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory Biomarker Correlations and Prognosis in High-risk Gastrointestinal Stromal Tumor Patients: A Multicenter Retrospective Analysis;2024-01-30

2. A giant gastrointestinal stromal tumor revealed by a life-threatening hematemesis: A case report of a rare entity and a challenging management;International Journal of Surgery Case Reports;2024-01

3. Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors;International Journal of Hyperthermia;2023-12-30

4. Gastric, Duodenal, and Small Bowel Emergencies;Surgical Clinics of North America;2023-12

5. Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging;Abdominal Radiology;2023-11-25